Income Statement

ZENAS BIOPHARMA, INC.

ZBIO
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY
Revenue
10.00 5.00
Cost of Revenue
- -
Gross Profit
10.00 5.00
Operating Expenses
393.06 168.89
Research & Development
168.06 139.14
Selling, General & Administrative
53.32 29.75
Other Operating Expenses
- -
Operating Income
-383.06 -163.89
Non-Operating Income
5.24 7.33
Interest Income
12.15 -
Interest Expense
- -
Other Non-Op Income / Expense
0.42 8.18
Income Before Tax
-377.82 -156.56
Income Tax Expense
-0.08 0.43
Non-Controlling Interest
- -
Net Income
-377.74 -156.99
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY
Depreciation & Amortization
- -
EBITDA
-383.06 -163.89
Earnings Per Share (Basic)
-8.44 -11.89
Diluted EPS
-8.44 -11.89
Weighted Average Shares
44.73 13.20
Diluted Weighted Avg Shares
44.73 13.20
Comprehensive Income
-378.00 -156.83